Pharmabiz18h
Telix to buy next-generation therapeutic assets and innovative biologics technology platform from ImaginAb
Telix, a commercial-stage biopharmaceutical company, announces it has entered into an asset purchase agreement with antibody engineering company ImaginAb, Inc. (ImaginAb) to acquire a pipeline of next ...
Pharmabiz20h
Illumina launches pilot proteomics programme with UK Biobank and biopharma collaborators to analyze 50,000 samples
Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced a pilot proteomics programme to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, ...
Pharmabiz1h
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...
Pharmabiz2h
BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi
BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...
Pharmabiz16h
Telix enters agreement with Curium Pharma for transfer of marketing and distribution rights for Scintimun
Telix, a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic (‘theranostic’) radiopharmaceuticals, announces that it has entered ...
Pharmabiz3h
REGENXBIO & Nippon Shinyaku enter exclusive partnership to develop and commercialize RGX-121 and RGX-111 for MPS diseases
Rockville, Maryland Wednesday, January 15, 2025, 12:00 Hrs [IST] ...
Pharmabiz3h
SATB launches ‘Addressing The Twin Epidemics: Survivor Led Framework’ to integrate mental health and TB care
Our Bureau, Mumbai Wednesday, January 15, 2025, 11:30 Hrs [IST] ...
Pharmabiz4h
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial
Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...
Pharmabiz3h
United We Care introduces United-MedASR, a most accurate medical automatic speech recognition
Deep tech startup United We Care (UWC) announced the launch of United-MedASR, an advanced Medical Automatic Speech Recognition (ASR) model, which sets new global benchmarks for clinical accuracy. The ...
Pharmabiz5h
Chugai Pharma to transfer future marketing of anti-cancer agent, Tarceva tablets 25, 100 & 150 in Japan to Cheplapharm
Chugai Pharma to transfer future marketing of anti-cancer agent, Tarceva tablets 25, 100 & 150 in Japan to Cheplapharm: Tokyo Wednesday, January 15, 2025, 10:00 Hrs [IST] Chugai P ...
Pharmabiz6h
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope
Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...
Pharmabiz7h
Drug supply to entire north east may collapse if more time is not given to comply with revised Schedule M: ASSPMA
Peethaambaran Kunnathoor, Chennai Wednesday, January 15, 2025, 08:00 Hrs [IST] ...